nodes	percent_of_prediction	percent_of_DWPC	metapath
Linezolid—MAOA—Clearance of dopamine—SLC6A3—malignant glioma	0.0347	0.123	CbGpPWpGaD
Linezolid—MAOA—Biogenic Amine Synthesis—ASMT—malignant glioma	0.0234	0.083	CbGpPWpGaD
Linezolid—Impaired healing—Carmustine—malignant glioma	0.0233	0.0362	CcSEcCtD
Linezolid—Myelosuppression—Carmustine—malignant glioma	0.0214	0.0334	CcSEcCtD
Linezolid—Myelosuppression—Temozolomide—malignant glioma	0.0207	0.0323	CcSEcCtD
Linezolid—Tongue discolouration—Temozolomide—malignant glioma	0.0201	0.0313	CcSEcCtD
Linezolid—Transient ischaemic attack—Temozolomide—malignant glioma	0.0193	0.03	CcSEcCtD
Linezolid—MAOA—Neurotransmitter Clearance In The Synaptic Cleft—BCHE—malignant glioma	0.0169	0.0597	CbGpPWpGaD
Linezolid—MAOA—Neurotransmitter Clearance In The Synaptic Cleft—SLC6A3—malignant glioma	0.0159	0.0562	CbGpPWpGaD
Linezolid—Oral candidiasis—Carmustine—malignant glioma	0.0158	0.0247	CcSEcCtD
Linezolid—Oral candidiasis—Temozolomide—malignant glioma	0.0153	0.0238	CcSEcCtD
Linezolid—MAOB—Tryptophan metabolism—ASMT—malignant glioma	0.0152	0.054	CbGpPWpGaD
Linezolid—MAOB—Dopamine metabolism—SOD1—malignant glioma	0.0149	0.0526	CbGpPWpGaD
Linezolid—MAOB—Alpha-synuclein signaling—PARK2—malignant glioma	0.0119	0.0422	CbGpPWpGaD
Linezolid—Drug interaction—Carmustine—malignant glioma	0.0108	0.0169	CcSEcCtD
Linezolid—Vaginal inflammation—Temozolomide—malignant glioma	0.00972	0.0151	CcSEcCtD
Linezolid—Candida infection—Carmustine—malignant glioma	0.0096	0.015	CcSEcCtD
Linezolid—Neuropathy—Carmustine—malignant glioma	0.00944	0.0147	CcSEcCtD
Linezolid—MAOB—Tryptophan metabolism—CYP2C18—malignant glioma	0.00941	0.0333	CbGpPWpGaD
Linezolid—MAOA—Dopamine metabolism—SOD1—malignant glioma	0.00932	0.033	CbGpPWpGaD
Linezolid—Candida infection—Temozolomide—malignant glioma	0.00928	0.0145	CcSEcCtD
Linezolid—Vaginal infection—Temozolomide—malignant glioma	0.00918	0.0143	CcSEcCtD
Linezolid—Neuropathy—Temozolomide—malignant glioma	0.00912	0.0142	CcSEcCtD
Linezolid—Sepsis—Carmustine—malignant glioma	0.00873	0.0136	CcSEcCtD
Linezolid—MAOB—Alpha-synuclein signaling—SLC6A3—malignant glioma	0.00855	0.0303	CbGpPWpGaD
Linezolid—Phlebitis—Carmustine—malignant glioma	0.00847	0.0132	CcSEcCtD
Linezolid—Thrombophlebitis—Carmustine—malignant glioma	0.00843	0.0131	CcSEcCtD
Linezolid—Thrombophlebitis—Temozolomide—malignant glioma	0.00815	0.0127	CcSEcCtD
Linezolid—Injury—Carmustine—malignant glioma	0.00794	0.0124	CcSEcCtD
Linezolid—Thirst—Temozolomide—malignant glioma	0.00741	0.0115	CcSEcCtD
Linezolid—Hyponatraemia—Carmustine—malignant glioma	0.00733	0.0114	CcSEcCtD
Linezolid—Gastrointestinal haemorrhage—Carmustine—malignant glioma	0.0073	0.0114	CcSEcCtD
Linezolid—MAOB—Phase 1 - Functionalization of compounds—CYP2B6—malignant glioma	0.00711	0.0252	CbGpPWpGaD
Linezolid—Liver function test abnormal—Carmustine—malignant glioma	0.00674	0.0105	CcSEcCtD
Linezolid—Hypokalaemia—Carmustine—malignant glioma	0.00664	0.0103	CcSEcCtD
Linezolid—MAOB—embryo—malignant glioma	0.00658	0.0869	CbGeAlD
Linezolid—Hypokalaemia—Temozolomide—malignant glioma	0.00642	0.01	CcSEcCtD
Linezolid—Aspartate aminotransferase increased—Temozolomide—malignant glioma	0.00635	0.0099	CcSEcCtD
Linezolid—Alanine aminotransferase increased—Temozolomide—malignant glioma	0.00622	0.00969	CcSEcCtD
Linezolid—MAOB—Phase 1 - Functionalization of compounds—CYP2C18—malignant glioma	0.00617	0.0219	CbGpPWpGaD
Linezolid—MAOB—brainstem—malignant glioma	0.00603	0.0796	CbGeAlD
Linezolid—Pancytopenia—Carmustine—malignant glioma	0.00599	0.00933	CcSEcCtD
Linezolid—Sweating increased—Temozolomide—malignant glioma	0.00594	0.00925	CcSEcCtD
Linezolid—Neutropenia—Carmustine—malignant glioma	0.0059	0.00919	CcSEcCtD
Linezolid—Pancytopenia—Temozolomide—malignant glioma	0.00579	0.00902	CcSEcCtD
Linezolid—Neutropenia—Temozolomide—malignant glioma	0.0057	0.00888	CcSEcCtD
Linezolid—Hyperglycaemia—Carmustine—malignant glioma	0.00569	0.00887	CcSEcCtD
Linezolid—Upper respiratory tract infection—Temozolomide—malignant glioma	0.00567	0.00883	CcSEcCtD
Linezolid—Pneumonia—Carmustine—malignant glioma	0.00566	0.00881	CcSEcCtD
Linezolid—MAOA—embryo—malignant glioma	0.00562	0.0741	CbGeAlD
Linezolid—Renal failure—Carmustine—malignant glioma	0.00553	0.00861	CcSEcCtD
Linezolid—Neuropathy peripheral—Carmustine—malignant glioma	0.00551	0.00859	CcSEcCtD
Linezolid—Hyperglycaemia—Temozolomide—malignant glioma	0.0055	0.00857	CcSEcCtD
Linezolid—Stomatitis—Carmustine—malignant glioma	0.00548	0.00854	CcSEcCtD
Linezolid—Pneumonia—Temozolomide—malignant glioma	0.00547	0.00852	CcSEcCtD
Linezolid—Stevens-Johnson syndrome—Temozolomide—malignant glioma	0.00539	0.0084	CcSEcCtD
Linezolid—MAOB—telencephalon—malignant glioma	0.00535	0.0706	CbGeAlD
Linezolid—Neuropathy peripheral—Temozolomide—malignant glioma	0.00533	0.0083	CcSEcCtD
Linezolid—Stomatitis—Temozolomide—malignant glioma	0.0053	0.00825	CcSEcCtD
Linezolid—MAOA—brainstem—malignant glioma	0.00515	0.0679	CbGeAlD
Linezolid—MAOB—Tryptophan metabolism—CAT—malignant glioma	0.00513	0.0182	CbGpPWpGaD
Linezolid—MAOB—Alpha-synuclein signaling—BAD—malignant glioma	0.0051	0.0181	CbGpPWpGaD
Linezolid—Haemoglobin—Carmustine—malignant glioma	0.00508	0.00791	CcSEcCtD
Linezolid—Haemorrhage—Carmustine—malignant glioma	0.00505	0.00787	CcSEcCtD
Linezolid—Hypoaesthesia—Carmustine—malignant glioma	0.00502	0.00783	CcSEcCtD
Linezolid—MAOA—Serotonin Transporter Activity—IL1B—malignant glioma	0.00501	0.0178	CbGpPWpGaD
Linezolid—MAOA—retina—malignant glioma	0.00497	0.0655	CbGeAlD
Linezolid—Haemoglobin—Temozolomide—malignant glioma	0.00491	0.00764	CcSEcCtD
Linezolid—Haemorrhage—Temozolomide—malignant glioma	0.00488	0.0076	CcSEcCtD
Linezolid—Hypoaesthesia—Temozolomide—malignant glioma	0.00486	0.00756	CcSEcCtD
Linezolid—Pharyngitis—Temozolomide—malignant glioma	0.00484	0.00755	CcSEcCtD
Linezolid—MAOA—Oxidative Stress—SOD1—malignant glioma	0.00477	0.0169	CbGpPWpGaD
Linezolid—MAOB—Phase 1 - Functionalization of compounds—PTGS1—malignant glioma	0.00467	0.0166	CbGpPWpGaD
Linezolid—Erythema multiforme—Temozolomide—malignant glioma	0.00461	0.00719	CcSEcCtD
Linezolid—MAOA—telencephalon—malignant glioma	0.00457	0.0603	CbGeAlD
Linezolid—Tinnitus—Temozolomide—malignant glioma	0.00455	0.00709	CcSEcCtD
Linezolid—MAOA—Oxidative Stress—CAT—malignant glioma	0.00453	0.0161	CbGpPWpGaD
Linezolid—MAOA—Phase 1 - Functionalization of compounds—CYP2B6—malignant glioma	0.00446	0.0158	CbGpPWpGaD
Linezolid—Erythema—Carmustine—malignant glioma	0.0044	0.00685	CcSEcCtD
Linezolid—Chills—Temozolomide—malignant glioma	0.00438	0.00682	CcSEcCtD
Linezolid—Erythema—Temozolomide—malignant glioma	0.00425	0.00662	CcSEcCtD
Linezolid—MAOB—medulla oblongata—malignant glioma	0.00421	0.0555	CbGeAlD
Linezolid—Dysgeusia—Temozolomide—malignant glioma	0.00416	0.00648	CcSEcCtD
Linezolid—Vision blurred—Carmustine—malignant glioma	0.00414	0.00645	CcSEcCtD
Linezolid—Anaemia—Carmustine—malignant glioma	0.00406	0.00633	CcSEcCtD
Linezolid—Vision blurred—Temozolomide—malignant glioma	0.004	0.00624	CcSEcCtD
Linezolid—Leukopenia—Carmustine—malignant glioma	0.00394	0.00613	CcSEcCtD
Linezolid—Anaemia—Temozolomide—malignant glioma	0.00393	0.00612	CcSEcCtD
Linezolid—Angioedema—Temozolomide—malignant glioma	0.00388	0.00605	CcSEcCtD
Linezolid—MAOA—Phase 1 - Functionalization of compounds—CYP2C18—malignant glioma	0.00387	0.0137	CbGpPWpGaD
Linezolid—MAOB—midbrain—malignant glioma	0.00384	0.0507	CbGeAlD
Linezolid—Vertigo—Temozolomide—malignant glioma	0.00382	0.00595	CcSEcCtD
Linezolid—Convulsion—Carmustine—malignant glioma	0.00381	0.00593	CcSEcCtD
Linezolid—Leukopenia—Temozolomide—malignant glioma	0.0038	0.00592	CcSEcCtD
Linezolid—Hypertension—Carmustine—malignant glioma	0.0038	0.00591	CcSEcCtD
Linezolid—MAOB—Biological oxidations—CYP2B6—malignant glioma	0.00378	0.0134	CbGpPWpGaD
Linezolid—MAOB—spinal cord—malignant glioma	0.00375	0.0495	CbGeAlD
Linezolid—Cough—Temozolomide—malignant glioma	0.00371	0.00578	CcSEcCtD
Linezolid—Convulsion—Temozolomide—malignant glioma	0.00368	0.00573	CcSEcCtD
Linezolid—Hypertension—Temozolomide—malignant glioma	0.00367	0.00571	CcSEcCtD
Linezolid—MAOA—medulla oblongata—malignant glioma	0.00359	0.0474	CbGeAlD
Linezolid—Dry mouth—Temozolomide—malignant glioma	0.00354	0.00551	CcSEcCtD
Linezolid—Thrombocytopenia—Carmustine—malignant glioma	0.00351	0.00547	CcSEcCtD
Linezolid—Anaphylactic shock—Temozolomide—malignant glioma	0.00347	0.0054	CcSEcCtD
Linezolid—Anorexia—Carmustine—malignant glioma	0.00342	0.00533	CcSEcCtD
Linezolid—Thrombocytopenia—Temozolomide—malignant glioma	0.00339	0.00529	CcSEcCtD
Linezolid—Skin disorder—Temozolomide—malignant glioma	0.00337	0.00525	CcSEcCtD
Linezolid—Hyperhidrosis—Temozolomide—malignant glioma	0.00335	0.00522	CcSEcCtD
Linezolid—Anorexia—Temozolomide—malignant glioma	0.00331	0.00515	CcSEcCtD
Linezolid—MAOA—midbrain—malignant glioma	0.00328	0.0433	CbGeAlD
Linezolid—MAOB—Biological oxidations—CYP2C18—malignant glioma	0.00328	0.0116	CbGpPWpGaD
Linezolid—Insomnia—Carmustine—malignant glioma	0.00325	0.00506	CcSEcCtD
Linezolid—Paraesthesia—Carmustine—malignant glioma	0.00322	0.00502	CcSEcCtD
Linezolid—MAOA—spinal cord—malignant glioma	0.0032	0.0422	CbGeAlD
Linezolid—Dyspnoea—Carmustine—malignant glioma	0.0032	0.00498	CcSEcCtD
Linezolid—Somnolence—Carmustine—malignant glioma	0.00319	0.00497	CcSEcCtD
Linezolid—Insomnia—Temozolomide—malignant glioma	0.00314	0.00489	CcSEcCtD
Linezolid—Decreased appetite—Carmustine—malignant glioma	0.00312	0.00486	CcSEcCtD
Linezolid—Paraesthesia—Temozolomide—malignant glioma	0.00311	0.00485	CcSEcCtD
Linezolid—Gastrointestinal disorder—Carmustine—malignant glioma	0.0031	0.00483	CcSEcCtD
Linezolid—Dyspnoea—Temozolomide—malignant glioma	0.00309	0.00482	CcSEcCtD
Linezolid—Somnolence—Temozolomide—malignant glioma	0.00308	0.0048	CcSEcCtD
Linezolid—Pain—Carmustine—malignant glioma	0.00307	0.00478	CcSEcCtD
Linezolid—Constipation—Carmustine—malignant glioma	0.00307	0.00478	CcSEcCtD
Linezolid—Dyspepsia—Temozolomide—malignant glioma	0.00305	0.00475	CcSEcCtD
Linezolid—MAOB—central nervous system—malignant glioma	0.00304	0.0402	CbGeAlD
Linezolid—Decreased appetite—Temozolomide—malignant glioma	0.00301	0.0047	CcSEcCtD
Linezolid—Gastrointestinal disorder—Temozolomide—malignant glioma	0.00299	0.00466	CcSEcCtD
Linezolid—Fatigue—Temozolomide—malignant glioma	0.00299	0.00466	CcSEcCtD
Linezolid—MAOB—cerebellum—malignant glioma	0.00297	0.0392	CbGeAlD
Linezolid—Constipation—Temozolomide—malignant glioma	0.00297	0.00462	CcSEcCtD
Linezolid—Pain—Temozolomide—malignant glioma	0.00297	0.00462	CcSEcCtD
Linezolid—Gastrointestinal pain—Carmustine—malignant glioma	0.00293	0.00457	CcSEcCtD
Linezolid—MAOA—Phase 1 - Functionalization of compounds—PTGS1—malignant glioma	0.00293	0.0104	CbGpPWpGaD
Linezolid—Abdominal pain—Carmustine—malignant glioma	0.00284	0.00442	CcSEcCtD
Linezolid—Body temperature increased—Carmustine—malignant glioma	0.00284	0.00442	CcSEcCtD
Linezolid—Gastrointestinal pain—Temozolomide—malignant glioma	0.00284	0.00442	CcSEcCtD
Linezolid—MAOB—Tryptophan metabolism—MDM2—malignant glioma	0.00284	0.01	CbGpPWpGaD
Linezolid—Urticaria—Temozolomide—malignant glioma	0.00275	0.00429	CcSEcCtD
Linezolid—Body temperature increased—Temozolomide—malignant glioma	0.00274	0.00427	CcSEcCtD
Linezolid—Abdominal pain—Temozolomide—malignant glioma	0.00274	0.00427	CcSEcCtD
Linezolid—MAOB—Biological oxidations—GSTT1—malignant glioma	0.00265	0.00939	CbGpPWpGaD
Linezolid—MAOA—central nervous system—malignant glioma	0.0026	0.0343	CbGeAlD
Linezolid—Asthenia—Carmustine—malignant glioma	0.00257	0.00401	CcSEcCtD
Linezolid—MAOA—cerebellum—malignant glioma	0.00254	0.0335	CbGeAlD
Linezolid—Asthenia—Temozolomide—malignant glioma	0.00249	0.00388	CcSEcCtD
Linezolid—MAOB—Biological oxidations—PTGS1—malignant glioma	0.00248	0.0088	CbGpPWpGaD
Linezolid—Diarrhoea—Carmustine—malignant glioma	0.00245	0.00382	CcSEcCtD
Linezolid—Pruritus—Temozolomide—malignant glioma	0.00245	0.00382	CcSEcCtD
Linezolid—MAOB—brain—malignant glioma	0.00242	0.0319	CbGeAlD
Linezolid—Dizziness—Carmustine—malignant glioma	0.00237	0.0037	CcSEcCtD
Linezolid—Diarrhoea—Temozolomide—malignant glioma	0.00237	0.0037	CcSEcCtD
Linezolid—MAOA—Biological oxidations—CYP2B6—malignant glioma	0.00237	0.0084	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—RUNX3—malignant glioma	0.00232	0.00821	CbGpPWpGaD
Linezolid—Dizziness—Temozolomide—malignant glioma	0.00229	0.00357	CcSEcCtD
Linezolid—Vomiting—Carmustine—malignant glioma	0.00228	0.00355	CcSEcCtD
Linezolid—Rash—Carmustine—malignant glioma	0.00226	0.00352	CcSEcCtD
Linezolid—Dermatitis—Carmustine—malignant glioma	0.00226	0.00352	CcSEcCtD
Linezolid—Headache—Carmustine—malignant glioma	0.00225	0.0035	CcSEcCtD
Linezolid—Vomiting—Temozolomide—malignant glioma	0.0022	0.00343	CcSEcCtD
Linezolid—Rash—Temozolomide—malignant glioma	0.00219	0.00341	CcSEcCtD
Linezolid—Dermatitis—Temozolomide—malignant glioma	0.00218	0.0034	CcSEcCtD
Linezolid—Headache—Temozolomide—malignant glioma	0.00217	0.00338	CcSEcCtD
Linezolid—MAOA—SIDS Susceptibility Pathways—MYB—malignant glioma	0.00214	0.00758	CbGpPWpGaD
Linezolid—Nausea—Carmustine—malignant glioma	0.00213	0.00332	CcSEcCtD
Linezolid—MAOA—SIDS Susceptibility Pathways—SOX2—malignant glioma	0.00207	0.00732	CbGpPWpGaD
Linezolid—MAOA—brain—malignant glioma	0.00206	0.0272	CbGeAlD
Linezolid—Nausea—Temozolomide—malignant glioma	0.00206	0.00321	CcSEcCtD
Linezolid—MAOA—Biological oxidations—CYP2C18—malignant glioma	0.00206	0.00728	CbGpPWpGaD
Linezolid—MAOB—Metabolism—RTEL1—malignant glioma	0.00186	0.00658	CbGpPWpGaD
Linezolid—MAOB—Biological oxidations—GSTP1—malignant glioma	0.00184	0.00651	CbGpPWpGaD
Linezolid—MAOA—Biological oxidations—GSTT1—malignant glioma	0.00166	0.00589	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—NTRK2—malignant glioma	0.00161	0.00569	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—YWHAE—malignant glioma	0.00161	0.00569	CbGpPWpGaD
Linezolid—MAOA—Biological oxidations—PTGS1—malignant glioma	0.00156	0.00552	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—GJA1—malignant glioma	0.00132	0.00468	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—BCHE—malignant glioma	0.00128	0.00455	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—SLC6A3—malignant glioma	0.00121	0.00428	CbGpPWpGaD
Linezolid—MAOA—Metabolism—RTEL1—malignant glioma	0.00117	0.00413	CbGpPWpGaD
Linezolid—MAOA—Biological oxidations—GSTP1—malignant glioma	0.00115	0.00408	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—HES1—malignant glioma	0.00115	0.00408	CbGpPWpGaD
Linezolid—MAOB—Metabolism—COX8A—malignant glioma	0.00107	0.00378	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—BCHE—malignant glioma	0.000984	0.00349	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—HIF1A—malignant glioma	0.000965	0.00342	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—SLC6A3—malignant glioma	0.000925	0.00328	CbGpPWpGaD
Linezolid—MAOB—Metabolism—ASMT—malignant glioma	0.000907	0.00321	CbGpPWpGaD
Linezolid—MAOB—Metabolism—BCAN—malignant glioma	0.000853	0.00302	CbGpPWpGaD
Linezolid—MAOB—Metabolism—IDH2—malignant glioma	0.000687	0.00244	CbGpPWpGaD
Linezolid—MAOA—Metabolism—COX8A—malignant glioma	0.000669	0.00237	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—BRAF—malignant glioma	0.000655	0.00232	CbGpPWpGaD
Linezolid—MAOB—Metabolism—CYP2B6—malignant glioma	0.000646	0.00229	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—CXCL8—malignant glioma	0.000626	0.00222	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—IL1B—malignant glioma	0.000601	0.00213	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—CASP3—malignant glioma	0.000599	0.00212	CbGpPWpGaD
Linezolid—MAOB—Metabolism—IDH1—malignant glioma	0.000591	0.00209	CbGpPWpGaD
Linezolid—MAOB—Metabolism—SPHK1—malignant glioma	0.000572	0.00203	CbGpPWpGaD
Linezolid—MAOA—Metabolism—ASMT—malignant glioma	0.000569	0.00202	CbGpPWpGaD
Linezolid—MAOB—Metabolism—CYP2C18—malignant glioma	0.00056	0.00199	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—MDM2—malignant glioma	0.000549	0.00194	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—RAF1—malignant glioma	0.000547	0.00194	CbGpPWpGaD
Linezolid—MAOA—Metabolism—BCAN—malignant glioma	0.000535	0.0019	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—VEGFA—malignant glioma	0.000509	0.0018	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—BRAF—malignant glioma	0.000502	0.00178	CbGpPWpGaD
Linezolid—MAOB—Metabolism—GSTT1—malignant glioma	0.000453	0.00161	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—TNF—malignant glioma	0.000436	0.00154	CbGpPWpGaD
Linezolid—MAOA—Metabolism—IDH2—malignant glioma	0.000431	0.00153	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PTGS1—malignant glioma	0.000425	0.0015	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—MDM2—malignant glioma	0.000421	0.00149	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—RAF1—malignant glioma	0.000419	0.00149	CbGpPWpGaD
Linezolid—MAOA—Metabolism—CYP2B6—malignant glioma	0.000406	0.00144	CbGpPWpGaD
Linezolid—MAOB—Metabolism—BCHE—malignant glioma	0.000395	0.0014	CbGpPWpGaD
Linezolid—MAOB—Metabolism—SLC5A5—malignant glioma	0.00039	0.00138	CbGpPWpGaD
Linezolid—MAOA—Metabolism—IDH1—malignant glioma	0.000371	0.00131	CbGpPWpGaD
Linezolid—MAOA—Metabolism—SPHK1—malignant glioma	0.000359	0.00127	CbGpPWpGaD
Linezolid—MAOA—Metabolism—CYP2C18—malignant glioma	0.000352	0.00125	CbGpPWpGaD
Linezolid—MAOB—Metabolism—GSTP1—malignant glioma	0.000314	0.00111	CbGpPWpGaD
Linezolid—MAOB—Metabolism—CAT—malignant glioma	0.000306	0.00108	CbGpPWpGaD
Linezolid—MAOB—Metabolism—NCOR1—malignant glioma	0.000289	0.00102	CbGpPWpGaD
Linezolid—MAOA—Metabolism—GSTT1—malignant glioma	0.000284	0.00101	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PTGS1—malignant glioma	0.000266	0.000944	CbGpPWpGaD
Linezolid—MAOA—Metabolism—BCHE—malignant glioma	0.000248	0.000878	CbGpPWpGaD
Linezolid—MAOA—Metabolism—SLC5A5—malignant glioma	0.000245	0.000867	CbGpPWpGaD
Linezolid—MAOB—Metabolism—CAV1—malignant glioma	0.000235	0.000834	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PIK3CG—malignant glioma	0.000214	0.000759	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PPARG—malignant glioma	0.000207	0.000733	CbGpPWpGaD
Linezolid—MAOA—Metabolism—GSTP1—malignant glioma	0.000197	0.000698	CbGpPWpGaD
Linezolid—MAOA—Metabolism—CAT—malignant glioma	0.000192	0.000679	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PIK3CD—malignant glioma	0.000188	0.000668	CbGpPWpGaD
Linezolid—MAOA—Metabolism—NCOR1—malignant glioma	0.000181	0.000642	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PIK3CB—malignant glioma	0.000164	0.000582	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PTGS2—malignant glioma	0.000163	0.000577	CbGpPWpGaD
Linezolid—MAOA—Metabolism—CAV1—malignant glioma	0.000148	0.000523	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PTEN—malignant glioma	0.000142	0.000503	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PIK3CG—malignant glioma	0.000134	0.000476	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PPARG—malignant glioma	0.00013	0.00046	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PIK3CD—malignant glioma	0.000118	0.000419	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PIK3CB—malignant glioma	0.000103	0.000365	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PTGS2—malignant glioma	0.000102	0.000362	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PIK3CA—malignant glioma	0.0001	0.000355	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PTEN—malignant glioma	8.91e-05	0.000315	CbGpPWpGaD
Linezolid—MAOB—Metabolism—AKT1—malignant glioma	8.18e-05	0.00029	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PIK3CA—malignant glioma	6.28e-05	0.000223	CbGpPWpGaD
Linezolid—MAOA—Metabolism—AKT1—malignant glioma	5.13e-05	0.000182	CbGpPWpGaD
